Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
作者： Hagop Kantarjian , Francis Giles , Lydia Wunderle , Kapil Bhalla , Susan O'Brien
DOI: 10.1056/NEJMOA055104
关键词: Nilotinib 、 Imatinib 、 Chronic myelogenous leukemia 、 Internal medicine 、 Hematologic Response 、 Acute lymphocytic leukemia 、 Blastic Phase 、 Cancer research 、 Medicine 、 Gastroenterology 、 Imatinib mesylate 、 Philadelphia chromosome
摘要: Background Resistance to imatinib mesylate can occur in chronic myelogenous leukemia (CML). Preclinical vitro studies have shown that nilotinib (AMN107), a new BCR-ABL tyrosine kinase inhibitor, is more potent than against CML cells by factor of 20 50. Methods In phase 1 dose-escalation study, we assigned 119 patients with imatinib-resistant or acute lymphoblastic (ALL) receive orally at doses 50 mg, 100 200 400 600 800 and 1200 mg once daily twice daily. Results Common adverse events were myelosuppression, transient indirect hyperbilirubinemia, rashes. Of 33 the blastic disease, 13 had hematologic response 9 cytogenetic response; 46 accelerated phase, 22 11 12 complete remission. Conclusions Nilotinib has relatively favorable safety profil...
elsevier.com
gacguidelines.ca 参考文章(21)
Srdan Verstovsek, Mirna Golemovic, Hagop Kantarjian, Tashi Manshouri, Zeev Estrov, Paul Manley, Tong Sun, Ralph B Arlinghaus, Leila Alland, Margaret Dugan, Jorge Cortes, Francis Giles, Miloslav Beran, None, AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells Cancer. ,vol. 104, pp. 1230- 1236 ,(2005) , 10.1002/CNCR.21299
John O'Quigley, Larry Z. Shen, Anthony Gamst, TWO-SAMPLE CONTINUAL REASSESSMENT METHOD Journal of Biopharmaceutical Statistics. ,vol. 9, pp. 17- 44 ,(1999) , 10.1081/BIP-100100998
Moshe Talpaz, Neil P. Shah, Hagop Kantarjian, Nicholas Donato, John Nicoll, Ron Paquette, Jorge Cortes, Susan O'Brien, Claude Nicaise, Eric Bleickardt, M. Anne Blackwood-Chirchir, Vishwanath Iyer, Tai-Tsang Chen, Fei Huang, Arthur P. Decillis, Charles L. Sawyers, Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias The New England Journal of Medicine. ,vol. 354, pp. 2531- 2541 ,(2006) , 10.1056/NEJMOA055229
Hagop M. Kantarjian, Michael J. Keating, Moshe Talpaz, Ronald S. Walters, Terry L. Smith, Ann Cork, Kenneth B. McCredie, Emil J. Freireich, Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients The American Journal of Medicine. ,vol. 83, pp. 445- 454 ,(1987) , 10.1016/0002-9343(87)90754-6
Michelle H. Tan, Zhengwu Sun, Sarah L. Opitz, Tracy E. Schmidt, John H. Peters, Elizabeth L. George, Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood. ,vol. 104, pp. 11- 18 ,(2004) , 10.1182/BLOOD-2003-09-3363
Hagop Kantarjian, Charles Sawyers, Andreas Hochhaus, Francois Guilhot, Charles Schiffer, Carlo Gambacorti-Passerini, Dietger Niederwieser, Debra Resta, Renaud Capdeville, Ulrike Zoellner, Moshe Talpaz, Brian Druker, None, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia The New England Journal of Medicine. ,vol. 346, pp. 645- 652 ,(2002) , 10.1056/NEJMOA011573
Stephen G O'Brien, François Guilhot, Richard A Larson, Insa Gathmann, Michele Baccarani, Francisco Cervantes, Jan J Cornelissen, Thomas Fischer, Andreas Hochhaus, Timothy Hughes, Klaus Lechner, Johan L Nielsen, Philippe Rousselot, Josy Reiffers, Giuseppe Saglio, John Shepherd, Bengt Simonsson, Alois Gratwohl, John M Goldman, Hagop Kantarjian, Kerry Taylor, Gregor Verhoef, Ann E Bolton, Renaud Capdeville, Brian J Druker, None, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia The New England Journal of Medicine. ,vol. 348, pp. 994- 1004 ,(2003) , 10.1056/NEJMOA022457
Hagop M. Kantarjian, Dennis Dixon, Michael J. Keating, Moshe Talpaz, Ronald S. Walters, Kenneth B. McCredie, Emil J Freireich, Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. ,vol. 61, pp. 1441- 1446 ,(1988) , 10.1002/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C
Stefan Faderl, Moshe Talpaz, Zeev Estrov, Hagop M. Kantarjian, Chronic Myelogenous Leukemia: Biology and Therapy Annals of Internal Medicine. ,vol. 131, pp. 207- 219 ,(1999) , 10.7326/0003-4819-131-3-199908030-00008
Michael W.N. Deininger, Stephen G. O’Brien, John M. Ford, Brian J. Druker, Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib Journal of Clinical Oncology. ,vol. 21, pp. 1637- 1647 ,(2003) , 10.1200/JCO.2003.11.143